Güngördük, KemalÖzdemir, AykutSelçuk, İlkerTelli, ElçinToptaş, TayfunAkman, LeventGüzel, Ahmet B.Taşkın, SalihÖge, TufanGüngördük, ÖzgüGökçü, MehmetGüngör, TayfunYaşar, LeventTerek, Mustafa C.Özsaran, AydınSancı, MuzafferVardar, Mehmet A.Meydanlı, Mehmet M.Yalçın, Ömer T.Ortaç, FıratÖzalp, Sinan2023-08-152023-08-152017-01-30Güngördük, K. vd. (2017). ''Comparison of early stage high grade serous primary fallopian tube cancers and epithelial ovarian cancers: A multicenter study''. Oncology Research and Treatment, 40(4), 203-209.2296-52702296-5262https://doi.org/10.1159/000458440https://karger.com/ort/article/40/4/203/263309/Comparison-Of-Early-Stage-High-Grade-Seroushttp://hdl.handle.net/11452/33501Introduction: We compared the disease free-survival (DFS) and overall survival (OS) rates of patients with high-grade serous primary fallopian tube cancer (HG-sPFTC) and high-grade serous epithelial ovarian cancer (HG-sEOC). Methods: 22 early-stage cancer patients (International Federation of Gynecology and Obstetrics (FIGO) stages I-II) with HG-sPFTC were retrospectively evaluated. In addition, 44 control patients diagnosed with HG-sEOC were matched to these patients with respect to tumor stage at diagnosis. All patients underwent complete surgical staging, followed by adjuvant chemotherapy. Kaplan-Meier curves were used to generate survival data. Results: The mean age of HG-sPFTC patients was 59.4 +/- 6.2 years, and that of HG-sEOC patients 55.2 +/- 11.0 years (p = 0.002). All patients underwent 6 cycles of platinum-based adjuvant chemotherapy. All operations were optimal. The 5-year DFSs were 77.3% for HG-sPFTC patients and 75% for HG-sEOC patients (p = 1.00).The 5-year OS rates were 81.8% in women with HG-sPFTC and 77.3% in those with HG-sEOC (p = 0.75). Conclusion: The DFS and OS rates of patients with early-stage (FIGO stages I and II) HG-sPFTC and HG-sEOC were similar. The surgical and adjuvant therapy management of these malignancies should be similar.eninfo:eu-repo/semantics/openAccessOncologyPrimary fallopian tube cancerEpithelial ovarian cancerHigh-grade serous cancerCarcinomaAdenocarcinomaAntineoplastic combined chemotherapy protocolsChemotherapy, adjuvantDiagnosis, differentialDisease free survivalEarly detection of cancerFallopian tube neoplasmsFemaleHumansMiddle agedNeoplasm gradingNeoplasms, glandular and epithelialOvarian neoplasmsPrevalenceReproducibility of resultsRisk factorsSensitivity and specificitySurvival rateTreatment outcomeTurkeyArticle0003988841000062-s2.0-8501714532220320640428376498OncologyFallopian Tubes; Salpingooophorectomy; HysterectomyCA 125 antigenCarboplatinPaclitaxelPlatinum derivativeAntineoplastic agentAdultArticleCancer adjuvant therapyCancer patientCancer recurrenceCancer stagingCase control studyClinical articleControlled studyDemographyDisease free survivalFemaleHigh grade serous primary fallopian tube cancerHumanKaplan meier methodMultiple cycle treatmentOvary carcinomaOverall survivalRetrospective studySalpingooophorectomySurgical techniqueUterine tube carcinomaAdjuvant chemotherapyCancer gradingClinical trialComparative studyControlled clinical trialDifferential diagnosisDisease free survivalEarly cancer diagnosisFallopian tube neoplasmsMiddle agedMortalityMulticenter studyNeoplasms, glandular and epithelialOvarian neoplasmsPathologyPrevalenceReproducibilityRisk factorSensitivity and specificityStatistics and numerical dataSurvival rateTreatment outcomeTurkey